Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents

Explore the diverse ways large B-cell lymphoma can manifest, the diagnostic process, and prognostic indicators for effective management.

Expert insight into current treatment strategies and emerging therapies for diffuse large B-cell lymphoma, a challenging malignancy.

Discover cutting-edge cellular therapeutics, CAR T-cell therapy, and bispecific strategies for treating lymphoma patients in clinical trials.

Gain insights into CAR T-cell therapy's impact on lymphoma treatment through a historical perspective and mechanism of action.

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.

Delve into the challenges of CAR T-cell therapy access and explore the biology behind treatment responses and relapses in lymphoma patients.

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.

Expert perspective on treatment sequencing strategies for patients with LBCL.

Expert perspective on advancements in cancer immunotherapy, including CAR-T cells, allogeneic strategies, and the role of bispecific antibodies.

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.